iVexSol
Chemicals & Related Products · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
20 Maguire Rd, Lexington, Massachusetts,...Phone Number
(617) 430-4990Website
www.ivexsol.comRevenue
$5.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About iVexSol
iVexSol is a cutting-edge lentiviral vector manufacturing company that specializes in Intelligent Manufacturing® solutions for clinical development programs. They offer highly scalable services including vector fitness testing, stable producer cell lines, and on-demand vector supply, thereby eliminating traditional production challenges. Their innovative technology aims to provide accessible CAR-T and advanced therapies by ensuring rapid and cost-effective vector production. Targeting biopharmaceutical companies and organizations involved in gene and cell therapies, iVexSol aims to transform the landscape of vector supply.Explore more
iVexSol Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is iVexSol your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if iVexSol has recently received funding, and reach out quickly before it becomes old news!
iVexSol, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if iVexSol had a recent Job posting/layoffs
Product Launch: Get notified when iVexSol launches new products
Congratulate Masked Content for being promoted to Masked Content at iVexSol
Check out if iVexSol is spiking on competitors!
Funding: Get notified immidiatlly once iVexSol has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on iVexSol recently announced quarterly report
Recommended Actions
Find VP level buyers at iVexSol
Find more new buyers
Compare Similar Companies to iVexSol
Compare insights from companies similar to iVexSol, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
iVexSol is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
iVexSol is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about iVexSol.
iVexSol financials insights
Gather financial insights about iVexSol, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$39M
iVexSol Tech Stack
A closer look at the technologies used by iVexSol
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Funding
Event
will be attending the Advanced Therapies Week conference as an exhibitor. The event will occur from January 17 to January 20, 2023.
Left Company
Executive Move
Funding
iVexSol News & Media
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total ofCellares to tackle key roadblock in cell therapy manufacturing with new partner iVexSol
Viral vector manufacturing and transduction processes today are lengthy and inconsistent SOUTH SAN FRANCISCO and LEXINGTON, Mass., Sept. 20, 2022 /PRNewswire/ --- Cellares Corporation, a life science technology company leading the way in cell therapy manufacturing automation, and iVexSol...IVEXSOL ANNOUNCES NEW SENIOR VICE PRESIDENT OF OPERATIONS
LEXINGTON, Mass., March 22, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company is pleased to announce the appointment of Sean Brown as Senior Vice President of Operations. Mr. Brown brings over 30 years of experience in clinical and commercial operations in the...Ivexsol Announces The Appointment Of Amitabha Deb, Ph.D.
LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company announces the appointment of Amitabha Deb, Ph.D. as Senior Vice President of Process Sciences and MS&T. Amitabha Deb, Ph.D. has 30 years of successful experience in the Biopharma...
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding iVexSol
Sign Up For FreeTo access detailed company insights
iVexSol is a cutting-edge lentiviral vector manufacturing company that specializes in Intelligent Manufacturing® solutions for clinical development programs. They offer highly scalable services including vector fitness testing, stable producer cell lines, and on-demand vector supply, thereby eliminating traditional production challenges. Their inno... Read More
